Citations

Clear

35 citation(s) found for "Chan, Wing C".

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Campo, Elı́as , Jaffe, Elaine S. , Cook, James R. , Quintanilla‐Martínez, Leticia , Brousset, Pierre , Cerroni, Lorenzo , Dirnhofer, Stefan , Friedberg, Jonathan W. , King, Rebecca L., Miguel, Jesús F. San , Seymour, John F. , Advani, Ranjana H. , Ansell, Stephen M. , Au, Wing-Yan, Bergsagel, Leif, Cohen, Jeffrey I. , d’Amore, Francesco, Ghobrial, Irene M. , Kim, Won-Seog, Kumar, Shaji , LaCasce, Ann S. , Laurent, Camille , Lenz, Georg, Leonard, John P. , Link, Michael P., López‐Guillermo, Armando , Mateos, María‐Victoria , Melnick, Ari , Nakamura, Shigeo, Narbaitz, Marina, Pavlovsky, Astrid , Pro, Barbara, Sander, Birgitta , Smith, Sonali M. , Staudt, Louis M. , Thieblemont, Catherine, Tousseyn, Thomas , Wilson, Wyndham H., Yoshino, Tadashi, Dreyling, Martin , Winter, Jane N., Bergsagel, P. Leif , Dirnhofer, S , Bergsagel, P. Leif , Brousset, Pierre , Dogan, Ahmet , Feldman, Andrew L , Ghia, Paolo , Salles, Gilles A , San-Miguel, Jesus , Seymour, John F , Treon, Steven , Vose, Julie , Zucca, Emanuele , Barrionuevo, Carlos , Davies, Andrew , Falini, Brunangelo , Ghobrial, Irene M , Goodlad, John R , Gribben, John G. , Hsi, Eric D , Kahl, Brad S , Kumar, Shaji K , LaCasce, Ann Steward , Mateos, María-Victoria , Macintyre, Elizabeth , Melnick, Ari , Morschhauser, Franck , Pileri, Stefano , Piris, Miguel , Rajkumar, Vincent, Shipp, Margaret Ann , Smith, Sonali M , Zinzani, Pier Luigi , Dreyling, Martin , Scott, David W , Zelenetz, Andrew D , Jaffe, Elaine S , Campo, Elías , Advani, Ranjana H , Quintanilla-Martinez, Leticia , Swerdlow, Steven H. , Anderson, Kenneth C. , Leval, Laurence de , Doǧan, Ahmet , Feldman, Andrew L. , Fend, Falko , Gaulard, Philippe , Ghia, Paolo , Horwitz, Steven M. , Salles, Gilles , Treon, Steven P. , Vose, Julie M. , Zucca, Emanuele , Chan, Wing C., Davies, Andrew , Falini, Brunangelo , Hsi, Eric D. , Kahl, Brad S. , Kim, Won Seog , Lenz, Georg , Macintyre, Elizabeth , Morschhauser, Franck , Pileri, Stefano , Piris, Miguel Á. , Rajkumar, S. Vincent , Rosen, Steven T. , Sehn, Laurie H. , Thiéblemont, Catherine , Wilson, Wyndham H. , Yoshino, Tadashi, Zinzani, Pier Luigi , Scott, David W. , Winter, Jane N. , Zelenetz, Andrew D.

Mayo Clinic

Blood | June 2, 2022 | Volume: 140 | Issue: 11 | Pages: 1229-1253

10.1182/blood.2022015851 | PMID 35653592 Get It

Abstract Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.
DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS
Herek, Tyler A. , Lone, Waseem , Sharma, Sunandini , Amador, Catalina , Heavican, Tayla B., Qi, Wei , Jochum, Dylan T. , Greiner, Timothy C. , Rosenwald, Andreas , Ott, German , Lim, Soon Thye , Ong, Choon Kiat , Wang, Gang Greg , Staudt, Louis M. , d’Amore, Francesco, Weisenburger, Dennis D. , Chan, Wing C. , Iqbal, Javeed , Bouska, Alyssa , Amador, Catalina , Heavican, Tayla B , Jochum, Dylan , Greiner, Timothy C , Smith, Lynette , Pileri, Stefano , Feldman, Andrew L , Lim, Soon Thye , Ong, Choon Kiat , Jaffe, Elaine S , Wang, Gang Greg , Vose, Julie , d'Amore, Francesco , Iqbal, Javeed , Lone, Waseem G , Li, Yuping , Wei, Qi, Smith, Lynette M. , Pileri, Stefano , Feldman, Andrew L. , Song, Joo Y. , Jaffe, Elaine S. , Rimsza, Lisa M. , Vose, Julie M.

Mayo Clinic

Blood | May 31, 2022 | Volume: 140 | Issue: 11 | Pages: 1278-1290

10.1182/blood.2021015019 | PMID 35639959 Get It

Abstract Peripheral T-cell lymphomas (PTCLs) are heterogenous T-cell neoplasms often associated with epigenetic dysregulation. We investigated de novo DNA methyltransferase 3A (DNMT3A) mutations in common PTCL entities, including angioimmunoblastic T-cell lymphoma and novel molecular subtypes identified within PTCL–not otherwise specified (PTCL-NOS) designated as PTCL-GATA3 and PTCL-TBX21. DNMT3A-mutated PTCL-TBX21 cases showed inferior overall survival (OS), with DNMT3A-mutated residues skewed toward the methyltransferase domain and dimerization motif (S881–R887). Transcriptional profiling demonstrated significant enrichment of activated CD8+ T-cell cytotoxic gene signatures in the DNMT3A-mutant PTCL-TBX21 cases, which was further validated using immunohistochemistry. Genomewide methylation analysis of DNMT3A-mutant vs wild-type (WT) PTCL-TBX21 cases demonstrated hypomethylation in target genes regulating interferon-γ (IFN-γ), T-cell receptor signaling, and EOMES (eomesodermin), a master transcriptional regulator of cytotoxic effector cells. Similar findings were observed in a murine model of PTCL with Dnmt3a loss (in vivo) and further validated in vitro by ectopic expression of DNMT3A mutants (DNMT3A-R882, -Q886, and -V716, vs WT) in CD8+ T-cell line, resulting in T-cell activation and EOMES upregulation. Furthermore, stable, ectopic expression of the DNMT3A mutants in primary CD3+ T-cell cultures resulted in the preferential outgrowth of CD8+ T cells with DNMT3AR882H mutation. Single-cell RNA sequencing(RNA-seq) analysis of CD3+ T cells revealed differential CD8+ T-cell subset polarization, mirroring findings in DNMT3A-mutated PTCL-TBX21 and validating the cytotoxic and T-cell memory transcriptional programs associated with the DNMT3AR882H mutation. Our findings indicate that DNMT3A mutations define a cytotoxic subset in PTCL-TBX21 with prognostic significance and thus may further refine pathological heterogeneity in PTCL-NOS and suggest alternative treatment strategies for this subset.
Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors
He, Zhijian , Deva, Sanjeev , Hung, Tak, Clarke, Katriona, Chao, Tsu‐Yi , Dai, Ming‐Shen , Yeh, Hsien‐Tang , Kramer, Douglas, Kwan, Rudolf, Cutler, David L. , Zhi, Jay, Jackson, Christopher , Segelov, Eva , Wee, Wen , Chan, Wing‐Kai

Mayo Clinic

CPT: Pharmacometrics & Systems Pharmacology | April 26, 2022 | Volume: 11 | Issue: 7 | Pages: 867-879

10.1002/psp4.12799 | PMID 35470967 Get It

AbstractOraxol consists of an oral dosage form of the chemotherapeutic agent paclitaxel administered with a novel P‐glycoprotein inhibitor encequidar methanesulfonate monohydrate (formerly named HM30181A), which allows oral treatment of cancers that would otherwise be treated with intravenous paclitaxel. Here we describe the population pharmacokinetics (popPK) analyses for oral paclitaxel in patients with advanced/metastatic solid tumors to characterize pharmacokinetic (PK) profiles and quantify sources of PK variability. The best fit popPK model for oral paclitaxel, based on data from seven clinical studies (197 patients with advanced/metastatic solid tumors), involves a linear two‐compartment structural model containing first‐order absorption with a short lag time and first‐order elimination as well as a log additive error. In this popPK model, lower population estimates of central volume for Asian patients versus Caucasian patients did not translate into clinical meaningful differences in oral paclitaxel exposure. Age, sex, body weight or surface area, mild hepatic impairment, and mild to moderate renal impairment had no clinically meaningful effects on the systemic exposure of oral paclitaxel. Simulations were performed on clinical therapeutic dose (oral paclitaxel 205 mg/m2 once daily ×3 days per week) to predict exposure of oral paclitaxel and to support treatment benefits observed in a pivotal phase III trial.
The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project
Slack, Graham W. , Farinha, Pedro , Cook, James R. , Ott, German , Rosenwald, Andreas , Amador, Catalina, Greiner, Timothy C. , Weisenburger, Dennis D. , Chan, Wing C. , Beiske, Klaus , Delabie, Jan , Delabie, Jan , Farinha, Pedro , Wong, Jasper , Collinge, Brett , Hilton, Laura K. , Ben‐Neriah, Susana , Salaverría, Itziar , Campo, Elı́as , Jaffe, Elaine S. , Raess, Philipp W. , Song, Joo Y. , Inghirami, Giorgio , Holte, Harald , Fu, Kai, Pittaluga, Stefania , Feldman, Andrew L. , Savage, Kerry J. , Mungall, Andrew J. , Steidl, Christian , Rimsza, Lisa M. , Morin, Ryan D , Scott, David W.

Mayo Clinic

Blood | November 23, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 1326-1326

10.1182/blood-2021-153441 Get It

Abstract Introduction: Plasmablastic lymphoma (PBL) is an aggressive B-cell lymphoma that predominantly occurs in patients with HIV or other causes of immunodeficiency. Frequent infection by the Epstein-Barr virus (EBV) and MYC translocations have been described as major features contributing to the pathogenesis of PBL. Prior studies examining the genetic landscape of PBL have largely relied on targeted capture-based sequencing approaches. As such, the molecular features of PBL remain to be fully explored. Here, we provide a comprehensive description of the genomic landscape of PBL using whole-genome and whole-exome sequencing to identify commonly perturbed pathways. Method: Archival diagnostic fresh frozen and formalin fixed paraffin embedded tissue biopsies from 58 PBL tumours were accrued from Lymphoma/Leukemia Molecular Profiling Project (LLMPP) sites, including 15 tumours from Ramis-Zaldivar et al., Haematolgica 2021. MYC rearrangements were identified by break-apart fluorescent in situ hybridization (FISH) and rearrangement partner was determined in a subset of tumours from capture or genome sequencing data using structural variant callers Manta, GRIDSS, and Delly. High confidence somatic mutations (SNVs/Indels) were identified in data from whole-genome (n=5) or whole-exome (n=53) sequencing through an ensemble voting approach utilizing four variant callers (Strelka2, Lofreq, Mutect2, SAGE). Mutation frequencies in known lymphoma-related genes were compared to activated B-cell (ABC)-DLBCL (Schmitz et al., NEJM 2018), as the closest tumour entity in terms of putative cell-of-origin differentiation stage, to identify differences in genetic aberrations. Candidate somatic copy number alterations (CNAs) were identified from exome and genome sequencing data, using CopywriteR and ControlFREEC, respectively, and high-confidence CNAs were determined using GISTIC2.0. Results: Within the study cohort, 81% of patients were male with a median age of 59 years (range 11-88). HIV and EBV statuses were available for 47% of patients and 95% of tumours, respectively, with 49% (13/27) of the patients being HIV+ and 69% (38/55) of tumours being EBV+. MYC rearrangement was observed in 60% (35/58) of PBLs, with IGH as the partner gene in 88% (21/24) of tumours. The most frequently mutated genes were STAT3 (38%), TP53 (22%), NRAS (21%), and TET2 (16%), consistent with previous studies, however novel mutations were seen in DUSP2 (21%), KLHL6 (16%), and BHLHE41 (16%). Recurrent CNAs included amplifications in 1q, whole gains of 7, 8q24, 11p12 and deletions affecting 4p16, 5p15, 10q11.22. While the mutational landscapes were similar between samples with and without a MYC translocation, the MYC-translocated PBLs showed more frequent amplification of 1q32.1. When stratifying by EBV status, STAT3 and SOCS1 mutations were more frequent in EBV-positive tumours, whereas TP53, TET2, KRAS, and MMRN2 mutations were associated with EBV-negativity. In comparison to ABC-DLBCL, PBLs were significantly enriched in STAT3 and NRAS mutations, and lacked common mutations affecting the NF-κB pathway (eg. MYD88, CD79B, and NFKBIZ 3' UTR mutations). Mutations in genes that are frequently mutated in ABC-DLBCLs, such as those associated with plasma cell differentiation (eg. PRDM1) or a memory B-cell fate (eg. TBL1XR1), were also not mutated in PBLs. Finally, genetic alterations associated with immune evasion, such as deletion of MHC I and II and mutations in B2M, CIITA, and CD58, were rarely observed. Conclusion: These data present a comprehensive overview of the genomic landscape of PBLs in a large cohort. We show frequent mutations involving the JAK-STAT and MAPK pathways, wherein the genetic landscape can be differentially characterized by EBV status and MYC rearrangement status. We show that PBLs are genetically distinct from ABC-DLBCLs, with absence of mutations in genes affecting the NF-κB pathway, immune evasion, and driving a memory B-cell fate. Disclosures Slack: Seagen: Consultancy, Honoraria. Raess: Scopio Labs: Research Funding. Holte: Gilead: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Nordic: Membership on an entity's Board of Directors or advisory committees; Nanovector: Membership on an entity's Board of Directors or advisory committees, Other: lectures honorarias; Novartis: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees. Savage: Servier: Consultancy, Honoraria; Roche: Research Funding; BMS: Consultancy, Honoraria, Other: Institutional clinical trial funding; Astra-Zeneca: Consultancy, Honoraria; Merck: Consultancy, Honoraria, Other: Institutional clinical trial funding; AbbVie: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria; Takeda: Other: Institutional clinical trial funding; Beigene: Other: Institutional clinical trial funding; Genentech: Research Funding. Steidl: Seattle Genetics: Consultancy; Curis Inc.: Consultancy; Bayer: Consultancy; Epizyme: Research Funding; Trillium Therapeutics: Research Funding; AbbVie: Consultancy; Bristol-Myers Squibb: Research Funding. Rimsza: NanoString Technologies: Other: Fee-for-service contract. Morin: Foundation for Burkitt Lymphoma Research: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy; Epizyme: Patents & Royalties. Scott: Abbvie: Consultancy; AstraZeneca: Consultancy; Rich/Genentech: Research Funding; BC Cancer: Patents & Royalties: Patent describing assigning DLBCL COO by gene expression profiling--licensed to NanoString Technologies. Patent describing measuring the proliferation signature in MCL using gene expression profiling. ; Incyte: Consultancy; Janssen: Consultancy, Research Funding; Celgene: Consultancy; NanoString Technologies: Patents & Royalties: Patent describing measuring the proliferation signature in MCL using gene expression profiling..
Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma
Lone, Waseem , Bouska, Alyssa , Sharma, Sunandini , Amador, Catalina, Herek, Tyler A. , Heavican, Tayla B., Yu, Jiayu , Lim, Soon Thye , Ong, Choon Kiat , Slack, Graham W. , Savage, Kerry J. , Rosenwald, Andreas , Ott, German , Cook, James R. , Greiner, Timothy C. , Weisenburger, Dennis D. , Motta, Giovanna , Chan, Wing C. , Iqbal, Javeed , Saumyaranjan, Mallick , Ong, Choon Kiat , Feldman, Andrew L , Weisenburger, Dennis D , Melle, Federica , Savage, Kerry J , Bouska, Alyssa , Iqbal, Javeed , Lone, Waseem G , Feldman, Andrew L. , Rimsza, Lisa M. , McKeithan, Timothy W. , Pileri, Stefano , Vose, Julie M.

Mayo Clinic

Clinical Cancer Research | August 23, 2021 | Volume: 27 | Issue: 21 | Pages: 6039-6053

10.1158/1078-0432.ccr-21-0573 | PMID 34426436 Get It

Abstract Purpose: Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non–Hodgkin lymphomas with aggressive clinical behavior. We performed comprehensive miRNA profiling in PTCLs and corresponding normal CD4+ Th1/2 and TFH-like polarized subsets to elucidate the role of miRNAs in T-cell lymphomagenesis. Experimental Design: We used nCounter (NanoString Inc) for miRNA profiling and validated using Taqman qRT-PCR (Applied Biosystems, Inc). Normal CD4+ T cells were polarized into effector Th subsets using signature cytokines, and miRNA significance was revealed using functional experiments. Results: Effector Th subsets showed distinct miRNA expression with corresponding transcription factor expression (e.g., BCL6/miR-19b, -106, -30d, -26b, in IL21-polarized; GATA3/miR-155, miR-337 in Th2-polarized; and TBX21/miR-181a, -331-3p in Th1-polarized cells). Integration of miRNA signatures suggested activation of TCR and PI3K signaling in IL21-polarized cells, ERK signaling in Th1-polarized cells, and AKT–mTOR signaling in Th2-polarized cells, validated at protein level. In neoplastic counterparts, distinctive miRNAs were identified and confirmed in an independent cohort. Integrative miRNA–mRNA analysis identified a decrease in target transcript abundance leading to deregulation of sphingolipid and Wnt signaling and epigenetic dysregulation in angioimmunoblastic T-cell lymphoma (AITL), while ERK, MAPK, and cell cycle were identified in PTCL subsets, and decreased target transcript abundance was validated in an independent cohort. Elevated expression of miRNAs (miR-126-3p, miR-145-5p) in AITL was associated with poor clinical outcome. In silico and experimental validation suggest two targets (miR-126→ SIPR2 and miR-145 → ROCK1) resulting in reduced RhoA-GTPase activity and T–B-cell interaction. Conclusions: Unique miRNAs and deregulated oncogenic pathways are associated with PTCL subtypes. Upregulated miRNA-126-3p and miR-145-5p expression regulate RhoA-GTPase and inhibit T-cell migration, crucial for AITL pathobiology.
EBV‐positive HIV‐associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features
Chapman, Jennifer R. , Bouska, Alyssa , Zhang, Weiwei , Alderuccio, Juan Pablo , Lossos, Izidore S. , Rimsza, Lisa M. , Maguire, Alanna , Yi, Shuhua , Chan, Wing C. , Song, Joo Y. , Maguire, Alanna , Rimsza, Lisa M , Song, Joo Y , Bouska, Alyssa , Vega, Francisco , Maguire, Alanna

Mayo Clinic

British Journal of Haematology | July 17, 2021 | Volume: 194 | Issue: 5 | Pages: 870-878

10.1111/bjh.17708 | PMID 34272731 Get It

Summary Even in the era of highly active combination antiretroviral therapy (cART), patients with HIV have a disproportionate risk of developing aggressive lymphomas that are frequently Epstein‐Barr virus (EBV)‐related. Here, we investigate HIV‐associated diffuse large B‐cell lymphoma (HIV‐DLBCL) and compare EBV‐positive and EBV‐negative cases. HIV‐DLBCL were identified from two academic medical centres and characterised by immunohistochemistry, EBV status, fluorescence in situ hybridisation, cell of origin determination by gene expression profiling, and targeted deep sequencing using a custom mutation panel of 334 genes. We also applied the Lymphgen tool to determine the genetic subtype of each case. Thirty HIV‐DLBCL were identified, with a median patient age of 46 years and male predominance (5:1). Thirteen cases (48%) were EBV‐positive and 14 (52%) EBV‐negative. Nine of the 16 tested cases (56%) had MYC rearrangement, three (19%) had BCL6 (two of which were double hit MYC / BCL6 ) and none had BCL2 rearrangements. Using the Lymphgen tool, half of the cases (15) were classified as other. All HIV‐DLBCL showed mutational abnormalities, the most frequent being TP53 (37%), MYC (30%), STAT3 (27%), HIST1H1E (23%), EP300 (20%), TET2 (20%), SOCS1 (17%) and SGK1 (17%). EBV‐negative cases were mostly of germinal centre B‐cell (GCB) origin (62%), showed more frequent mutations per case (a median of 13·5/case) and significant enrichment of TP53 (57% vs. 15%; P = 0·046), SGK1 (36% vs. 0%; P = 0·04), EP300 (43% vs. 0%; P = 0·02) and histone‐modifying gene (e.g. HIST1H1E , HIST1H1D , 79% vs. 31%; P = 0·02) mutations. EBV‐positive cases were mostly of non‐GCB origin (70%), with fewer mutations per case (median 8/case; P = 0·007), and these tumours were enriched for STAT3 mutations ( P = 0·10). EBV‐positive cases had a higher frequency of MYC mutations but the difference was not significant (36% vs. 15%; P = 0·38). EBV‐association was more frequent in HIV‐DLBCLs, arising in patients with lower CD4 counts at diagnosis (median 46·5 vs. 101, P = 0·018). In the era of cART, approximately half of HIV‐DLBCL are EBV‐related. HIV‐DLBCL are enriched for MYC rearrangements, MYC mutations and generally lack BCL2 rearrangements, regardless of EBV status. Among HIV‐DLBCL, tumours that are EBV‐negative and EBV‐positive appear to have important differences, the latter arising in context of lower CD4 count, showing frequent non‐GCB origin, lower mutation burden and recurrent STAT3 mutations.
Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling
Chen, Zhengshan , Chan, Lai N. , Klemm, Lars, Chan, Wing C. , Forman, Stephen J. , Berkel, Patrick van, Geng, Huimin , Luger, Selina M. , Litzow, Mark, Vaidehi, Nagarajan , Paietta, Elisabeth , Meffre, Eric , Weinstock, David M. , Müschen, Markus , Lee, Jae Woong , Kume, Kohei , Xiao, Gang , Cosgun, Kadriye Nehir , Chen, Liting , Chen, Chun‐Wei , Ma, Ning , Zammarchi, Francesca , Melnick, Ari , Ngo, Vu N. , McManus, Michael T.

Mayo Clinic

Blood | February 14, 2020 | Volume: 134 | Issue: Supplement_1 | Pages: 393-393

10.1182/blood-2019-131270 Get It

Background: Studying gene expression and clinical outcome data from 136 clinical trials for patients with cancer (~21,000 patients with 26 cancer types), we found CD25 as one of the strongest predictors of poor clinical outcome in patients with B-cell malignancies, but not in other cancer types. This was unexpected because CD25 is known as one of three chains of the IL2 receptor on T-cells and NK-cells. Interleukin-2 (IL2) functions as essential T-cell growth factor. IL2 signals through b- and g-, but not a-chains (CD25) of its heterotrimeric receptor. CD25-deficiency causes lymphoproliferation and autoimmunity, however, its mechanistic role is unclear. Results: Our experiments based on genetic mouse models and engineered patient-derived B-cell leukemia and lymphoma xenografts revealed that CD25 expressed on B-cells is not an IL2 receptor chain, but in fact binds downstream signaling molecules of the B-cell receptor (BCR). Through these interactions, CD25 mediates negative feedback to BCR signaling in response to antigen-encounter in normal B-cells. Defects in CD25-/-B-cells were not replicated in mice that express CD25 but lack expression of the IL2 cytokine. These findings demonstrate IL2-independent functions of CD25 in B-cells and B-cell derived leukemia and lymphoma. To comprehensively study the interactome of the short cytoplasmic tail of CD25, we performed proximity-dependent biotin identification (BioID). This analysis revealed that the CD25 tail exerts negative feedback control through recruitment of the PKCβ-scaffold RACK1 and the inhibitory phosphatase SHIP1 (see schematic, left). Interestingly, the cytoplasmic tail of CD25 harbors a PKCβ-substrate motif and mutation of a central serine residue (S268) to A268 compromised interactions with PKCβ, its scaffold RACK1 and SHIP1, demonstrating that feedback control was dependent on PKCβ-mediated phosphorylation of CD25-S268. A genetic observation in a family with monogenic autoimmunity confirmed the functional importance of the cytoplasmic CD25-tail motif: a mutation immediately preceding S268 compromised CD25-surface translocation, which was restored by homology-directed repair of the S268. In vitro kinase assay with 62 candidate kinases against recombinant cytoplasmic tail of CD25-S268 or -A268 identified PKCβ as top-ranking kinase hit for CD25-S268 but not CD25-A268. Our genetic studies revealed that PKCβ is required for cell-membrane translocation of CD25, but also transcriptional expression of CD25 via NF-κB activation. Therefore, PKCβ act as critical effector molecule downstream of CD25 to mediate B-cell selection during normal B-cell development and calibrate oncogenic BCR signaling in B-cell tumors. In B-cell malignancies, BCR-dependent survival and proliferation signals are often substituted by oncogenic BCR-mimics (e.g. BCR-ABL1, JAK2, BRAFV600E, LMP2A, CD79B mutations; see schematic, right). Accordingly, we identified CD25 surface-expression as biomarker of oncogenic BCR-signaling and predictor of poor clinical outcomes. CD25-/-B-cell leukemia failed to initiate fatal disease in transplant recipients. Owing to imbalances of oncogenic BCR-signaling and p53-checkpoint activation, CD25-/- B-cell leukemia failed to initiate fatal disease in transplant recipients. In patient-derived xenograft models of drug-resistant B-cell malignancies, treatment with a CD25-specific antibody drug-conjugate (ADCT-301) extended survival of transplant recipients or eradicated disease. These findings identified CD25 as previously unrecognized feedback regulator of oncogenic BCR-signaling and provide a rationale for therapeutic targeting of CD25 in refractory B-cell malignancies. Figure Disclosures Zammarchi: ADC Therapeutics: Employment. Van Berkel:ADC Therapeutics: Research Funding. Melnick:Constellation: Consultancy; Janssen: Research Funding; Epizyme: Consultancy. Luger:Celgene: Research Funding; Cyslacel: Research Funding; Pfizer: Honoraria; Seattle Genetics: Research Funding; Agios: Honoraria; Ariad: Research Funding; Biosight: Research Funding; Kura: Research Funding; Onconova: Research Funding; Genetech: Research Funding; Jazz: Honoraria; Daichi Sankyo: Honoraria. Meffre:AbbVie: Consultancy, Other: Grant. Weinstock:Celgene: Research Funding.